The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy

Current Cardiology Reports

Volumn 15, Issue 5, 2013, Pages

  Klein, Thomas ^a   Dilsizian, Vasken ^a   Cao, Qi ^a   Chen, Wengen ^a   Dickfeld, Timm Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Ablation therapy; Cardiac arrhythmia; Cardiac mIBG; Cardiomyopathy; Heart failure; Ventricular tachycardia

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; TRACER;

ADRENERGIC SYSTEM; ARTICLE; CARDIOMYOPATHY; COMPUTER ASSISTED TOMOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED VENTRICULAR TACHYCARDIA;

EID: 84875283887     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0359-1     Document Type: Article

References (72)

1. Zheng ZJ, Croft JB, GilesWH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-63. (Pubitemid 33043293)
2. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44:1268-75. (Pubitemid 39208884)
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83. (Pubitemid 34984635)
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. (Pubitemid 40110811)
5. Myerburg RJ, Interian Jr A, Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997;80:10F-9F. (Pubitemid 27377820)
6. Myerburg RJ, Mitrani R, Interian Jr A, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97:1514-21. (Pubitemid 28191308)
7. Moss AJ, Greenberg H, Case RB, ZarebaW, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-5. (Pubitemid 40023973)
8. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-484.
9. Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. JACC Cardiovasc Imaging. 2010;3:111-6.
10. Dae MW, DeMarco T, Botvinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med. 1992;33:1444-50.
11. Flotats A, Carrio I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802-12.
12. Veltman CE, Boogers MJ, Meinardi JE, et al. Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599-608.
13. ChenW, Cao Q, Dilsizian V. Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections. Curr Cardiol Rep. 2011;13:132-7.
14. Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969-74.
15. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
16. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134:550-60. (Pubitemid 32245316)
17. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287:883-9. (Pubitemid 34252037)
18. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-7.
19. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186-94. (Pubitemid 40248490)
20. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759-66.
21. Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231-8. (Pubitemid 36092191)
22. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535-46.
23. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, EhimeMIBG. Heart Failure Study Investigators. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J. 2001;65:155-60.
24. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917-23. (Pubitemid 29269210)
25. Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656-60. (Pubitemid 33086883)
26. Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608-15. (Pubitemid 36050207)
27. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol. 2005;28:304-10. (Pubitemid 40613059)
28. Gould PA, Kong G, Kalff V, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace. 2007;9:751-6. (Pubitemid 47371648)
29. Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging. 2010;3:64-70.
30. Burri H, Sunthorn H, Somsen A, et al. Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace. 2008;10:374-8. (Pubitemid 351773736)
31. Nishioka SA, MartinelliFilho M, Brandao SC, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007;14:852-9. (Pubitemid 350082581)
32. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147-59. (Pubitemid 351844881)
33. Dilsizian V, Chandrashekhar Y, Narula J. Introduction of new tests: low are the mountains, high the expectations. JACC Cardiovasc Imaging. 2010;3:117-9.
34. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212-21.
35. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;6:579-90. (Pubitemid 29015414)
36. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574-81. (Pubitemid 36223322)
37. Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation. 2000;101:1960-9. (Pubitemid 30225278)
38. Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation. 1990;82:103-13.
39. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236-42.
40. Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol. 1989;14:1519-26. (Pubitemid 19279053)
41. Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol. 1993;22:1344-53. (Pubitemid 23316357)
42. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-31. (Pubitemid 36503797)
43. Paul M, Schafers M, Kies P, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging. 2006;33:866-70. (Pubitemid 44127434)
44. Akutsu Y, Kaneko K, Kodama Y, et al. The significance of cardiac sympathetic nervous system abnormality in the long-term prognosis of patients with a history of ventricular tachyarrhythmia. J Nucl Med. 2009;50:61-7.
45. Nishisato K, Hashimoto A, Nakata T, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010;51:1241-9.
46. Paul M, Wichter T, Kies P, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med. 2011;52:1559-65.
47. Terai H, Shimizu M, Ino H, et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol. 2003;10:304-10. (Pubitemid 36758076)
48. Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart. 2012;98:1359-65.
49. Miranda CH, Figueiredo AB, Maciel BC, Marin-Neto JA, Simoes MV. Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with 123Imetaiodobenzylguanidine in chronic Chagas cardiomyopathy. J Nucl Med. 2011;52:504-10.
50. Bax JJ, Kraft O, Buxton AE, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131-40.
51. Kasama S, Toyama T, Kaneko Y, et al. Relationship between late ventricular potentials andmyocardial 123I-metaiodobenzylguanidine scintigraphy in patients with dilated cardiomyopathy with mild to moderate heart failure: results of a prospective study of sudden death events. Eur J Nucl Med Mol Imaging. 2012;39:1056-64.
52. Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213-8. (Pubitemid 47492905)
53. Koutelou M, Katsikis A, Flevari P, et al. Predictive value of cardiac autonomic indexes and MIBG washout in ICD recipients with mild to moderate heart failure. Ann Nucl Med. 2009;23:677-84.
54. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769-77.
55. Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702-6. (Pubitemid 34157373)
56. Kies P, Paul M, Gerss J, et al. Impaired cardiac sympathetic innervation in symptomatic patients with long QT syndrome. Eur J Nucl Med Mol Imaging. 2011;38:1899-907.
57. Daliento L, Folino AF, Menti L, Zanco P, Baratella MC, Dalla VS. Adrenergic nervous activity in patients after surgical correction of tetralogy of Fallot. J Am Coll Cardiol. 2001;38:2043-7. (Pubitemid 33116582)
58. Dickfeld T, Lei P, Dilsizian V, et al. Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. JACC Cardiovasc Imaging. 2008;1:73-82. (Pubitemid 351445384)
59. Tian J, Smith MF, Ahmad G, Dilsizian V, Jimenez A, Dickfeld T. Integration of 3-dimensional scar models from SPECT to guide ventricular tachycardia ablation. J Nucl Med. 2012;53:894-901.
60. Tian J, Jeudy J, Smith MF, et al. Three-dimensional contrastenhanced multidetector CT for anatomic, dynamic, and perfusion characterization of abnormal myocardium to guide ventricular tachycardia ablations. Circ Arrhythmelectrophysiol. 2010;3:496-504.
61. Tian J, Ahmad G, Mesubi O, Jeudy J, Dickfeld T. Threedimensional delayed-enhanced cardiac MRI reconstructions to guide ventricular tachycardia ablations and assess ablation lesions. Circ Arrhythmelectrophysiol. 2012;5:e31-5.
62. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101:1288-96. (Pubitemid 30158617)
63. Shekhar R, Walimbe V, Raja S, et al. Automated 3-dimensional elastic registration of whole-body PET and CT from separate or combined scanners. J Nucl Med. 2005;46:1488-96. (Pubitemid 46177969)
64. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42. (Pubitemid 34262671)
65. Ahmad G, Mesubi O, Dickfeld T, et al. Assessment of Regional Cardiac Innervation Using I123-Meta-iodobenzylguanidine for Guiding Ventricular Tachycardia Ablation [abstract]. In: Scientific Sessions-Heart Rhythm Society 2012; May 9-12, 2012; Boston, MA.
66. Klein T, Mesubi O, Ahmad G, et al. Assessment of Global Cardiac Innervation Using I123-Meta-iodobenzylguanidine Before and After Ventricular Tachycardia Ablation [abstract]. In: Scientific Sessions-American Heart Association 2012; November 4-6, 2012; Los Angeles, CA.
67. Langer O, Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur J Nucl Med Mol Imaging. 2002;29:416-34. (Pubitemid 34253256)
68. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54:1-15.
69. Vesalainen RK, Pietila M, Tahvanainen KU, et al. Cardiac positron emission tomography imaging with [11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Am J Cardiol. 1999;84:568-74. (Pubitemid 29408590)
70. Pietila M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28:373-6.
71. Sasano T, Abraham MR, Chang KC, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266-75. (Pubitemid 351754990)
72. Fallavollita JA, Luisi Jr AJ, Michalek SM, et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials. 2006;27:374-88. (Pubitemid 44202446)